Cooperation of Dominant Oncogenes with Regulatory Germline Variants Shapes Clinical Outcomes in Childhood Cancer

Julian Musa, Florencia Cidre-Aranaz, Marie-Ming Aynaud, Martin F Orth, Olivier Mirabeau, Mor Varon, Sandrine Grossetête, Didier Surdez, Shunya Ohmura, Julia S Gerke, Barak Rotblat

Research output: Working paper/PreprintPreprint

Abstract

Deciphering principles of inter-individual tumor heterogeneity is essential for refinement of personalized anti-cancer therapy. Unlike cancers of adulthood, pediatric malignancies including Ewing sarcoma (EwS) feature a striking paucity of somatic alterations except for pathognomonic driver-mutations that cannot explain overt variations in clinical outcome. Here we demonstrate in the EwS model how cooperation of a dominant oncogene and regulatory variants determine tumor growth, patient survival and drug response. We show that binding of the oncogenic EWSR1-FLI1 fusion transcription factor to a polymorphic enhancer-like DNA element controls expression of the transcription factor MYBL2, whose high expression promotes poor patient outcome via activation of pro-proliferative signatures. Analysis of paired germline and tumor whole-genome sequencing data revealed that regulatory variability at this locus is inherited via the germline. CRISPR-mediated interference with this regulatory element almost abolished MYBL2 transcription, and MYBL2 knockdown decreased cell proliferation, cell survival and tumorigenicity of EwS cells. Combined RNA- and ChIP-seq analyses as well as functional experiments and clinical data identified CCNF, BIRC5 and AURKB as direct MYBL2 targets and critical mediators of its phenotype. In drug-response experiments, high MYBL2 levels sensitized EwS cells for inhibition of its activating cyclin dependent kinase CDK2 in vitro and in vivo, suggesting MYBL2 as a predictive biomarker for targeted anti-CDK2-therapy. Collectively, our findings establish cooperation of somatic mutations and regulatory germline variants as a major determinant of tumor progression and indicate the importance of integrating the regulatory genome in the process of developing new diagnostic and/or therapeutic strategies to fully harness the potential of precision medicine.
Original languageEnglish GB
Number of pages1
StatePublished - 2018

Publication series

NamebioRxiv
PublisherCold Spring Harbor Laboratory Press

Fingerprint

Dive into the research topics of 'Cooperation of Dominant Oncogenes with Regulatory Germline Variants Shapes Clinical Outcomes in Childhood Cancer'. Together they form a unique fingerprint.

Cite this